Smart money still holding out for payday. Share price cheaper today than what most paid on average, around 3.0c from my calculations.
Most deals for antibody drugs done prior to phase 1 as confirmed by Patrys and they are mostly huge deals. 2023 the deals will flow for PAB imo . I can see us get a few deals , deoxymab platform unique.
From last Presentation
Deoxymabs bind to DNA and have a unique combination of properties:
• Cancer seeking: tumours release DNA which attracts deoxymabs
• Cell penetrating: able to get into cells and the cell nucleus
• Block DNA damage repair(DDR): stops cancer cells replicating
• Cross the blood-brain barrier(BBB): to treat cancers in the brain
• Not dependent on cell surface markers: broad utility across multiple cancers
Preclinical: deoxymabs safe with very little effect on normal, healthy cells.
No reported safety issues in previous clinicaltrials ofrelated antibodies
Fund Manager Mason Stevens holding 9.9% as reported in last presentation , around 208m shares .
Dr Dax Marcus Calder – 11.2% , around 235m shares.
Kerry Stokes (Kemast Investments ×2 ) and the wife (Mrs Christine Simpson Stokes) hold together almost 50m shares.
PAB TOP Holders, page-28
-
- There are more pages in this discussion • 113 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
